Galina Dorland
A5008817964- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Pancreatitis Pathology and Treatment
- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
- Viral Infections and Immunology Research
- Abdominal Surgery and Complications
- Radiomics and Machine Learning in Medical Imaging
- Neuroendocrine Tumor Research Advances
- Cardiac, Anesthesia and Surgical Outcomes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Sarcoidosis and Beryllium Toxicity Research
- Hemodynamic Monitoring and Therapy
- Cholangiocarcinoma and Gallbladder Cancer Studies
St. Antonius Ziekenhuis
2020-2024
University Medical Center Utrecht
2020-2024
Utrecht University
2020-2024
University of Amsterdam
2020-2022
Amsterdam University Medical Centers
2020-2022
Abstract Background Novel definitions suggest that resectability status for pancreatic ductal adenocarcinoma (PDAC) should be assessed beyond anatomical criteria, considering both biological and conditional factors. This has, however, yet to validated on a nationwide scale. study evaluated the prognostic value of factors staging patients with resectable PDAC. Patients Methods A observational cohort was performed, including all consecutive who underwent upfront resection National...
The prognostic value of four proposed modifications to the 8th American Joint Committee on Cancer (AJCC) TNM staging system has yet be evaluated. This study aimed validate five modifications.Patients who underwent pancreatic ductal adenocarcinoma resection (2014-2016), as registered in prospective Dutch Pancreatic Audit, were included. Stratification and prognostication systems assessed using Kaplan-Meier curves, Cox proportional hazard analyses, C-indices. A new modification was composed...
BackgroundThis study aimed to identify predictors for early and very disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma (PDAC) with without neoadjuvant therapy.MethodsIncluded were who underwent PDAC (2014–2016). Multivariable multinomial regression was performed preoperative manifestation within 3, 6 12 months after resection.Results836 a median follow-up 37 (interquartile range [IQR] 30–48) overall survival 18 (IQR 10-32) analyzed. 670 (80%) developed...
Carbohydrate antigen (CA) 19-9 is an established perioperative prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC). However, it unclear how CA19-9 monitoring should be used during postoperative surveillance to detect recurrence and guide the initiation of recurrence-focused therapy.
Abstract Background Intraoperative driving pressure (ΔP) has an independent association with the development of postoperative pulmonary complications (PPCs) in patients receiving ventilation during general anesthesia for major surgery. Ventilation high intraoperative positive end–expiratory (PEEP) recruitment maneuvers (RMs) that result a low ΔP potential to prevent PPCs. This trial tests hypothesis compared standard PEEP without RMs, individualized strategy, titrated lowest ΔP, RMs prevents...